Evidence map›Paper›PMID 35078527›Full record

ArticleGenome medicine2022

Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling.

Paul Vinu Salachan, Martin Rasmussen, Jacob Fredsøe, Benedicte Ulhøi, Michael Borre, Karina Dalsgaard Sørensen

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. The therapeutic potential of circular RNAs.Nature reviews. Genetics · 2025
    Review
  15. Review
  16. Review
  17. Prostate and urinary microbiomes in prostate cancer development: focus onFrontiers in cellular and infection microbiology · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Paul Vinu SalachanDepartment of Molecular Medicine, Aarhus University Hospital, 8200, Aarhus N, Denmark.
Martin RasmussenDepartment of Molecular Medicine, Aarhus University Hospital, 8200, Aarhus N, Denmark.
Jacob FredsøeDepartment of Molecular Medicine, Aarhus University Hospital, 8200, Aarhus N, Denmark.
Benedicte UlhøiDepartment of Pathology, Aarhus University Hospital, 8200, Aarhus N, Denmark.
Michael BorreDepartment of Clinical Medicine, Aarhus University, 8200, Aarhus N, Denmark.
Karina Dalsgaard SørensenDepartment of Molecular Medicine, Aarhus University Hospital, 8200, Aarhus N, Denmark. kdso@clin.au.dk.ORCID 0000-0002-4902-5490
Aarhus University · DKAarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith over 350,000 estimated deaths worldwide in 2018, prostate cancer (PCa) continues to be a major health concern and a significant cause of cancer-associated mortality among men. While cancer in general is considered a disease of the human genome, there is a growing body of evidence suggesting that changes to the healthy microbiota could play a vital role in cancer development, progression, and/or treatment outcome.

methodsUsing a metatranscriptomic approach, we annotated the microbial reads obtained from total RNA sequencing of 106 prostate tissue samples from 94 PCa patients (discovery cohort). We investigated microbial dysbiosis associated with PCa by systematically comparing the microbiomes between benign and malignant tissue samples, between less vs. more-aggressive PCa, and between patients who had biochemical recurrence as opposed to those who did not. We further performed differential gene expression and cell type enrichment analysis to explore the host transcriptomic and cellular responses to selected microbial genera. A public dataset (GSE115414) of total RNA sequencing reads from 24 prostate tissue samples (8 benign and 16 malignant) served as the validation cohort.

resultsWe observed decreased species diversity and significant under-representation of Staphylococcus saprophyticus and Vibrio parahaemolyticus, as well as significant over-abundance of Shewanella in malignant as compared to benign prostate tissue samples in both the discovery (p < 0.01) and validation (p < 0.05) cohorts. In addition, we identified Microbacterium species (p < 0.01) to be significantly over-abundant in pathologically advanced T3 tumors compared to T2 in the discovery cohort. Malignant samples having high vs. low Shewanella counts were associated with downregulated Toll-like receptor signaling pathways and decreased enrichment of dendritic cells. Malignant samples having low vs. high V. parahaemolyticus counts were enriched for olfactory transduction and drug metabolism pathways. Finally, malignant samples were enriched for M1 and M2 macrophages as compared to benign tissue samples.

conclusionsThe results from this exploratory study support the existence of an important biological link between the prostate microbiota and PCa development/progression. Our results highlight Shewanella, V. parahaemolyticus, and Microbacterium sp. as interesting candidates for further investigation of their association with PCa.

Indexed as

MicrobiotaProstatic NeoplasmsGene Expression ProfilingHumansMaleProstateTranscriptomeDendritic cellsMetatranscriptomeMicrobacterium sp.MicrobiomeProstate cancerShewanellaVibrio parahaemolyticus

Identifiers

PMID35078527
PMCPMC8787950
OpenAlexW4207041249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.